Search Results

There are 7997497 results for: content related to: Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis

  1. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults

    Intervention Review

    The Cochrane Library

    Vicente Ruiz Garcia, Amanda Burls, Juan B Cabello, Paloma Vela Casasempere, Sylvia Bort-Marti and José A Bernal

    Published Online : 8 SEP 2017, DOI: 10.1002/14651858.CD007649.pub4

  2. ARCHIVEDCochrane Clinical Answers

    Is there randomized controlled trial evidence to support the use of certolizumab (CDP870) in adults with rheumatoid arthritis?

    DOI: 10.1002/cca.569
  3. Adverse effects of biologics: a network meta-analysis and Cochrane overview

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara J Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell and Rachelle Buchbinder

    Published Online : 16 FEB 2011, DOI: 10.1002/14651858.CD008794.pub2

  4. You have free access to this content
    Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn’s disease

    Alimentary Pharmacology & Therapeutics

    Volume 29, Issue 6, March 2009, Pages: 605–614, L.-M. SHAO, M.-Y. CHEN, Q.-Y. CHEN and J.-T. CAI

    Version of Record online : 13 JAN 2009, DOI: 10.1111/j.1365-2036.2009.03929.x

  5. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  6. You have free access to this content
    Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two–week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

    Arthritis & Rheumatism

    Volume 58, Issue 11, November 2008, Pages: 3319–3329, Edward Keystone, Désireé Van Der Heijde, David Mason Jr., Robert Landewé, Ronald Van Vollenhoven, Bernard Combe, Paul Emery, Vibeke Strand, Philip Mease, Chintu Desai and Karel Pavelka

    Version of Record online : 30 OCT 2008, DOI: 10.1002/art.23964

  7. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  8. You have free access to this content
    Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study

    Alimentary Pharmacology & Therapeutics

    Volume 31, Issue 12, June 2010, Pages: 1276–1285, B. G. FEAGAN, M. C. REILLY, L. GERLIER, Y. BRABANT, M. BROWN and S. SCHREIBER

    Version of Record online : 18 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04303.x

  9. You have free access to this content
    Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab

    Journal of Digestive Diseases

    Volume 12, Issue 5, October 2011, Pages: 379–383, Himanshu Dev VERMA, Ellen Janice SCHERL, Vinita Elizabeth JACOB and Brian Paul BOSWORTH

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1751-2980.2011.00522.x

  10. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Brian W Behm and Stephen J Bickston

    Published Online : 23 JAN 2008, DOI: 10.1002/14651858.CD006893

  11. You have free access to this content
    American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: Data from a 52-week phase III trial

    Arthritis Care & Research

    Volume 63, Issue 1, January 2011, Pages: 128–134, R. F. van Vollenhoven, D. Felson, V. Strand, M. E. Weinblatt, K. Luijtens and E. C. Keystone

    Version of Record online : 28 DEC 2010, DOI: 10.1002/acr.20331

  12. You have free access to this content
    Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis

    Overview of Reviews

    The Cochrane Library

    Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Ahmed Kotb, Robin Christensen, Amy S Mudano, Lara J Maxwell, Nipam P Shah, Peter Tugwell and George A Wells

    Published Online : 13 MAY 2016, DOI: 10.1002/14651858.CD012183

  13. You have free access to this content
    Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 5, March 2011, Pages: 541–550, B. G. Feagan, W. J. Sandborn, D. C. Wolf, G. Coteur, O. Purcaru, Y. Brabant and P. J. Rutgeerts

    Version of Record online : 12 JAN 2011, DOI: 10.1111/j.1365-2036.2010.04568.x

  14. You have free access to this content
    Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease – subgroup results from a placebo-controlled study

    Alimentary Pharmacology & Therapeutics

    Volume 33, Issue 2, January 2011, Pages: 185–193, S. Schreiber, I. C. Lawrance, O. Ø. Thomsen, S. B. Hanauer, R. Bloomfield and W. J. Sandborn

    Version of Record online : 17 NOV 2010, DOI: 10.1111/j.1365-2036.2010.04509.x

  15. You have free access to this content
    2017 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 69, Issue S10, October 2017, Pages: 1–4426,

    Version of Record online : 27 SEP 2017, DOI: 10.1002/art.40321

  16. Are we moving forward in the biological treatment of Crohn's disease? time will tell

    Inflammatory Bowel Diseases

    Volume 12, Issue 2, February 2006, Pages: 147–149, Ioannis Oikonomou and Bo Shen

    Version of Record online : 14 DEC 2006, DOI: 10.1097/01.MIB.0000201820.79995.df

  17. You have free access to this content
    Practical application of anti-TNF therapy for luminal Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 11, November 2011, Pages: 2366–2391, Michael A. Kamm, Siew C. Ng, Peter De Cruz, Patrick Allen and Stephen B. Hanauer

    Version of Record online : 18 FEB 2011, DOI: 10.1002/ibd.21655

  18. You have free access to this content
    Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 4, August 2015, Pages: 428–440, W. Moon, L. Pestana, B. Becker, E. V. Loftus Jr, K. A. Hanson, D. H. Bruining, W. J. Tremaine and S. V. Kane

    Version of Record online : 17 JUN 2015, DOI: 10.1111/apt.13288

  19. Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 36, Issue 8, August 2016, Pages: 861–869, Paweł Kawalec, Pawel Moćko, Andrzej Pilc, Maria Radziwon-Zalewska and Iwona Malinowska-Lipień

    Version of Record online : 11 JUL 2016, DOI: 10.1002/phar.1784